Press Inquiry Form
If you are a journalist, editor, or media representative interested in covering AIMA and our innovations, please fill out the form below. We will get back to you as soon as possible.
A Tool for Diagnostic Optimization
Enhances the accuracy and speed of test interpretation.
Early Access
Suitable for those who monitor their health or are undergoing treatment.
Case Study: How AI Interpretation Turned a One-Time Test into Lifetime Loyalty
An anonymized case from a mid-sized independent laboratory in US. Figures are rounded and presented with the client's consent.
The problem
The laboratory had a familiar pattern: a patient came in for a blood test, received a report full of numbers and reference ranges — and left. No follow-up, no loyalty, no additional revenue. When a nearby competitor began offering interpretation of test results, patients started moving there.
What they did
They added Aima Diagnostics' AI interpretation on top of their existing workflow. Patients upload their results and receive a plain-language report covering correlations between biomarkers, patterns and abnormalities that may be difficult to identify when biomarkers are viewed individually, and personalized recommendations.
No equipment replacement. No staff retraining. Deployment took 5 weeks.
Results after 6 months
Why it worked
The product was never the test itself. Laboratories sell certainty and understanding. A page of numbers is raw data, not a finished product — and patients who can't interpret it will turn to whoever can. The AI report closes exactly that gap.
The incentive was in the economics, not in marketing. Every patient with an interpreted report had a concrete reason to return: repeat testing, comparison with previous results, follow-up consultation. The laboratory stopped paying to reacquire customers it had already served once.
Implementation carried almost no operational risk. An interpretation layer on top of existing results — no new equipment, no workflow overhaul. The commercial impact was measurable from the first month.
Accumulated data created a switching cost. Aima Diagnostics preserves each patient's longitudinal history — previous results, biomarker trends, identified risks. Once that picture exists, changing providers means losing it. Loyalty built this way doesn't depend on discounts; it depends on continuity.
The takeaway
A one-time blood test is a transaction. An interpreted result with longitudinal history is a relationship. The difference between the two is a single layer of software on top of the services this laboratory already provided.
The laboratory had a familiar pattern: a patient came in for a blood test, received a report full of numbers and reference ranges — and left. No follow-up, no loyalty, no additional revenue. When a nearby competitor began offering interpretation of test results, patients started moving there.
What they did
They added Aima Diagnostics' AI interpretation on top of their existing workflow. Patients upload their results and receive a plain-language report covering correlations between biomarkers, patterns and abnormalities that may be difficult to identify when biomarkers are viewed individually, and personalized recommendations.
No equipment replacement. No staff retraining. Deployment took 5 weeks.
Results after 6 months
- Repeat visit rate rose from 12% to 16% — patients returned to track changes over time instead of ordering a one-off test elsewhere.
- Average revenue per patient grew 20%, driven by orders for broader testing panels.
- Complaints about "unclear results" fell by half.
- Patient attrition to the competitor stopped. Interpretation became the laboratory's differentiator — not the competitor's.
Why it worked
The product was never the test itself. Laboratories sell certainty and understanding. A page of numbers is raw data, not a finished product — and patients who can't interpret it will turn to whoever can. The AI report closes exactly that gap.
The incentive was in the economics, not in marketing. Every patient with an interpreted report had a concrete reason to return: repeat testing, comparison with previous results, follow-up consultation. The laboratory stopped paying to reacquire customers it had already served once.
Implementation carried almost no operational risk. An interpretation layer on top of existing results — no new equipment, no workflow overhaul. The commercial impact was measurable from the first month.
Accumulated data created a switching cost. Aima Diagnostics preserves each patient's longitudinal history — previous results, biomarker trends, identified risks. Once that picture exists, changing providers means losing it. Loyalty built this way doesn't depend on discounts; it depends on continuity.
The takeaway
A one-time blood test is a transaction. An interpreted result with longitudinal history is a relationship. The difference between the two is a single layer of software on top of the services this laboratory already provided.
